German and Austrian antitrust authorities have approved a deal for Merck & Co. to acquire Acceleron Pharma for $11.5 billion, or $180 a share. The company specializes in the development of protein therapies for cancer treatment, as well as the search and development of drugs for rare hematological and lung diseases. The deal is scheduled to close in Q4 2021.